open access

Vol 88, No 5 (2020)
Review paper
Submitted: 2020-05-24
Accepted: 2020-08-01
Published online: 2020-10-30
Get Citation

Short-acting inhaled β2-agonists: why, whom, what, how?

Andrzej Emeryk1, Justyna Emeryk-Maksymiuk2
DOI: 10.5603/ARM.a2020.0132
·
Pubmed: 33169817
·
Adv Respir Med 2020;88(5):443-449.
Affiliations
  1. Klinika Chorób Płuc i Reumatologii Dziecięcej, Uniwersytet Medyczny w Lublinie
  2. Katedra i Zakład Pielęgniarstwa Internistycznego, Uniwersytet Medyczny w Lublinie

open access

Vol 88, No 5 (2020)
REVIEWS
Submitted: 2020-05-24
Accepted: 2020-08-01
Published online: 2020-10-30

Abstract

We showed the present data about the efficacy and safety of inhaled short-acting β2-agonists (SABA), such as salbutamol and fenoterol, in the management of obstructive diseases in children and adults. Our work discusses major mechanisms of action, clinical effects, possible side effects and indications of inhaled SABA. We presented current recommendations for the position of SABA in the therapy of obstructive diseases in children and adults, particularly in asthma and chronic obstructive pulmonary disease.

Abstract

We showed the present data about the efficacy and safety of inhaled short-acting β2-agonists (SABA), such as salbutamol and fenoterol, in the management of obstructive diseases in children and adults. Our work discusses major mechanisms of action, clinical effects, possible side effects and indications of inhaled SABA. We presented current recommendations for the position of SABA in the therapy of obstructive diseases in children and adults, particularly in asthma and chronic obstructive pulmonary disease.

Get Citation

Keywords

short-acting β2-agonist; salbutamol; fenoterol; inhalation; nebulization; asthma; COPD

About this article
Title

Short-acting inhaled β2-agonists: why, whom, what, how?

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 5 (2020)

Article type

Review paper

Pages

443-449

Published online

2020-10-30

DOI

10.5603/ARM.a2020.0132

Pubmed

33169817

Bibliographic record

Adv Respir Med 2020;88(5):443-449.

Keywords

short-acting β2-agonist
salbutamol
fenoterol
inhalation
nebulization
asthma
COPD

Authors

Andrzej Emeryk
Justyna Emeryk-Maksymiuk

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl